View ValuationCurexo 향후 성장Future 기준 점검 4/6Curexo은 연간 수입과 매출이 각각 61.1%와 17.4% 증가할 것으로 예상되고 EPS는 연간 61.9%만큼 증가할 것으로 예상됩니다.핵심 정보61.1%이익 성장률61.87%EPS 성장률Consumer Retailing 이익 성장24.3%매출 성장률17.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트07 Mar 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 23Curexo Inc. announced that it expects to receive KRW 500 million in fundingCurexo Inc. announced a private placement of Series 3 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 500,000,000 on April 22, 2026. The transaction involves participation from individual investor Ha Yong-chan for KRW 200,000,000, Yoon Seon-joong for KRW 200,000,000 and Yoo Jun-il for KRW 100,000,000. The Bonds are 100% convertible into 31,174 Common Shares of the company at a conversion price of KRW 16,039 and the conversion billing period will start from April 30, 2027 till March 31, 2029. The Bonds carry an interest rate of 3% and maturity interest of 4%. The Bonds have a maturity date of April 30, 2029. The transaction has been approved by Board of Directors of the company. The securities being issued in this transaction are on a hold period for 1 year. The transaction is expected to close on April 30, 2026.공시 • Feb 06Curexo Inc., Annual General Meeting, Mar 26, 2026Curexo Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South KoreaNew Risk • Feb 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (74% accrual ratio).공시 • Feb 08Curexo Inc., Annual General Meeting, Mar 26, 2025Curexo Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South KoreaNew Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).New Risk • Jul 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (74% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.3% increase in shares outstanding).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • May 22CUREXO Corp. Spinal Surgery Robot, 'Cuvis-Spine' Acquires FDA (US) LicensingCUREXO Corp. announced their independently developed spinal surgery robot 'CUVIS-spine' has acquired FDA (US) licensing. This FDA (US) license, followed by Korea (2019) and Europe CE (2020) certificate is the 3rd license that they have acquired and now their product can be supplied to all countries. Currently, 2 'CUVIS-spine's are being used in Severance Hospital (Korea) and 1 has been exported to an Australian medical facility company. CUREXO also plans to expand their focus on global markets including the US and Europe. Spinal surgery robot 'CUVIS-spine' is a next-gen spinal surgery robot that guides the insertion of a pedicle screw according to the surgery plan. It uses a high precision robot arm, wireless one-step, navigation based on a real-time GPS sensor to provide precise, safe and faster surgery compared to traditional manual surgery. Also, it minimizes the filming and reduces the radiation exposure of both patients and medical staff. Both 2-dimensional filming (C-arm) and 3-dimensional filming (O-arm) are applicable with this solution which provides great expandability. With the Wireless One-step and the robot system, it allows multiple steps (Needle, K-wire, Dilation, Tapping) of traditional manual surgery to be performed with one surgery tool and it reduces surgery duration greatly. It allows Minimally Invasive Surgery (MIS) which means that the patient's recovery time will be quicker compared to manual surgery.공시 • May 21Curexo Inc. announced that it has received KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment ArmOn May 20, 2021, Curexo Inc. (KOSDAQ:A060280) closed the transaction.공시 • May 14Curexo Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm and another investorCurexo Inc. (KOSDAQ:A060280) announced a private placement of round 2 non-guaranteed private equity convertible bonds for gross proceeds of KRW 15,000,000,000 on May 13, 2021. The bonds do not carry any coupon. The bonds will mature on May 20, 2026. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Investment Arm and Global Robot Healthcare New Technology Business Fund. The bonds are 100% convertible into 1,434,165 common shares at a price of KRW 10,459 per share. The conversion period of the bonds is from May 20, 2022 to April 20, 2026. The transaction is expected to close on May 20, 2021. The transaction has been approved by the board of directors of the company.공시 • Feb 10Curexo Inc., Annual General Meeting, Mar 24, 2021Curexo Inc., Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Jan 05New 90-day high: ₩7,170The company is up 14% from its price of ₩6,310 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 9.0% over the same period.이익 및 매출 성장 예측KOSDAQ:A060280 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202797,7008,100N/AN/A112/31/202688,7006,100N/AN/A13/31/202670,9182,137-7,017-4,820N/A12/31/202574,5322,771-13,772-11,258N/A9/30/202568,569-4,355-10,575-7,109N/A6/30/202564,580-6,744-8,279-3,300N/A3/31/202561,299-7,295-2,968530N/A12/31/202455,531-8,7584653,850N/A9/30/201627,848-16,147N/A-41,183N/A6/30/201627,540-12,602N/A-28,787N/A3/31/201627,957-10,978N/A-20,201N/A12/31/201527,530-9,402N/A-19,789N/A9/30/201528,708-9,238N/A-17,183N/A6/30/201527,426-11,394N/A-25,270N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A060280 의 연간 예상 수익 증가율(61.1%)이 saving rate(3.1%)보다 높습니다.수익 vs 시장: A060280 의 연간 수익(61.1%)이 KR 시장(31%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: A060280 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: A060280 의 수익(연간 17.4%)이 KR 시장(연간 15.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: A060280 의 수익(연간 17.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A060280의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YConsumer-retailing 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 02:43종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Curexo Inc.는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Song-hyup HanDaishin Securities Co. Ltd.Kyeongkeun KangNH Investment & Securities Co., Ltd.Jin-Hyoeng ParkYuanta Securities Korea Co., Ltd.
공시 • Apr 23Curexo Inc. announced that it expects to receive KRW 500 million in fundingCurexo Inc. announced a private placement of Series 3 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 500,000,000 on April 22, 2026. The transaction involves participation from individual investor Ha Yong-chan for KRW 200,000,000, Yoon Seon-joong for KRW 200,000,000 and Yoo Jun-il for KRW 100,000,000. The Bonds are 100% convertible into 31,174 Common Shares of the company at a conversion price of KRW 16,039 and the conversion billing period will start from April 30, 2027 till March 31, 2029. The Bonds carry an interest rate of 3% and maturity interest of 4%. The Bonds have a maturity date of April 30, 2029. The transaction has been approved by Board of Directors of the company. The securities being issued in this transaction are on a hold period for 1 year. The transaction is expected to close on April 30, 2026.
공시 • Feb 06Curexo Inc., Annual General Meeting, Mar 26, 2026Curexo Inc., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea
New Risk • Feb 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (74% accrual ratio).
공시 • Feb 08Curexo Inc., Annual General Meeting, Mar 26, 2025Curexo Inc., Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 114, taebong-ro, seocho-gu, seoul South Korea
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change).
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). High level of non-cash earnings (74% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
New Risk • Jul 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2016 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (74% accrual ratio). Minor Risk Shareholders have been diluted in the past year (5.3% increase in shares outstanding).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • May 22CUREXO Corp. Spinal Surgery Robot, 'Cuvis-Spine' Acquires FDA (US) LicensingCUREXO Corp. announced their independently developed spinal surgery robot 'CUVIS-spine' has acquired FDA (US) licensing. This FDA (US) license, followed by Korea (2019) and Europe CE (2020) certificate is the 3rd license that they have acquired and now their product can be supplied to all countries. Currently, 2 'CUVIS-spine's are being used in Severance Hospital (Korea) and 1 has been exported to an Australian medical facility company. CUREXO also plans to expand their focus on global markets including the US and Europe. Spinal surgery robot 'CUVIS-spine' is a next-gen spinal surgery robot that guides the insertion of a pedicle screw according to the surgery plan. It uses a high precision robot arm, wireless one-step, navigation based on a real-time GPS sensor to provide precise, safe and faster surgery compared to traditional manual surgery. Also, it minimizes the filming and reduces the radiation exposure of both patients and medical staff. Both 2-dimensional filming (C-arm) and 3-dimensional filming (O-arm) are applicable with this solution which provides great expandability. With the Wireless One-step and the robot system, it allows multiple steps (Needle, K-wire, Dilation, Tapping) of traditional manual surgery to be performed with one surgery tool and it reduces surgery duration greatly. It allows Minimally Invasive Surgery (MIS) which means that the patient's recovery time will be quicker compared to manual surgery.
공시 • May 21Curexo Inc. announced that it has received KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment ArmOn May 20, 2021, Curexo Inc. (KOSDAQ:A060280) closed the transaction.
공시 • May 14Curexo Inc. announced that it expects to receive KRW 15 billion in funding from Korea Investment & Securities Co., Ltd., Investment Arm and another investorCurexo Inc. (KOSDAQ:A060280) announced a private placement of round 2 non-guaranteed private equity convertible bonds for gross proceeds of KRW 15,000,000,000 on May 13, 2021. The bonds do not carry any coupon. The bonds will mature on May 20, 2026. The transaction will include participation from new investors Korea Investment & Securities Co., Ltd., Investment Arm and Global Robot Healthcare New Technology Business Fund. The bonds are 100% convertible into 1,434,165 common shares at a price of KRW 10,459 per share. The conversion period of the bonds is from May 20, 2022 to April 20, 2026. The transaction is expected to close on May 20, 2021. The transaction has been approved by the board of directors of the company.
공시 • Feb 10Curexo Inc., Annual General Meeting, Mar 24, 2021Curexo Inc., Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Jan 05New 90-day high: ₩7,170The company is up 14% from its price of ₩6,310 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 9.0% over the same period.